title: Antiretroviral therapy in AIDS patients with tuberculosis.
abstract: Tuberculosis associated with HIV infection continues to be an important problem throughout the world. Since the advent of HAART, the medication of HIV-infected patients who have to receive concomitant treatment for tuberculosis has become a difficult task. The two main problems faced by clinicians include the significant pharmacokinetic interactions between rifamycins, a cornerstone in antituberculosis therapy, and protease inhibitors and nonnucleoside reverse transcriptase inhibitors, which are essential components of antiretroviral combination regimens, as well as the best moment to initiate antiretroviral therapy in patients with tuberculosis. The therapy of choice for patients with no previous antiretroviral experience includes an antituberculous regimen with rifampin and an efavirenz-based antiretroviral regimen. No dose adjustments of these drugs seem to be necessary. Nevirapine can be an alternative to efavirenz in this situation. For patients who cannot take efavirenz, either due to resistance or intolerance, rifabutin and a boosted protease inhibitor can be coadministered, with the necessary dose adjustments. No definite recommendations can be given regarding the optimal timing of antiretroviral therapy, but a delay of two months after initiation of antituberculosis therapy would be advisable and seems to be safe in most patients.
authors.affiliation: Hospital Ramón y Cajal, Universidad de Alcalá, Madrid, Spain. smoreno.hrc@salud.madrid.org
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
authors.forename: Beatriz
authors.initials: B
authors.lastname: Hernández
authors.forename: Fernando
authors.initials: F
authors.lastname: Dronda
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000382:microbiology; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D000995:Antitubercular Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D004347:Drug Interactions; D006801:Humans; D011480:Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics*; D012294:Rifamycins / Q000009:adverse effects / Q000493:pharmacokinetics*; D014376:Tuberculosis / Q000188:drug therapy / Q000821:virology*
chemical_list: D000995:Antitubercular Agents; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D012294:Rifamycins